Retatrutide comparative results, long-acting TB medicine targets and climate-related health risks
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →
Asundexian approval, endometrial cancer priority review and osteosarcoma research
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Divarasib comparative lung cancer results and two gastric cancer trial updates
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Lung cancer combination results, ovarian cancer evidence and early prostate cancer research
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Multiple sclerosis trial results, pancreatic cancer subgroups and heat-health indicators
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Melanoma vaccine trial results, malaria vaccine pricing and an inflammation pipeline acquisition
Late-stage oncology evidence, vaccine affordability and an early-stage oral inflammation programme.
Read full update →Nigeria Ebola case, Ultomiris kidney-disease approval and WHO TB diagnostic evidence guidance
Outbreak preparedness, an accelerated regulatory approval and evidence standards for diagnostic development.
Read full update →Hepatitis B treatment approval, prescription companion apps and inequalities in NCD care
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Ebola diagnostics, bitopertin Phase III results and an oncology partnership
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Kenya Ebola update, India cancer-medicine pricing and six-year Miudella research
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Medicine quality, oncology collaboration and MERS surveillance
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Oral GLP-1 recommendation, thyroid eye disease treatment and maternal-health supplies
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Anktiva bladder cancer approval, FDA rare-disease initiative and lead poisoning prevention
An FDA oncology expansion, a rare-disease development framework and WHO lead-exposure prevention priorities.
Read full update →Kenya Ebola update, Liquidia’s Yutrepia settlement and reliable electricity for healthcare
Contact monitoring in Kenya, a pharmaceutical settlement and energy infrastructure for healthcare facilities.
Read full update →Proposed Keytruda biosimilar review, AI-designed metabolic medicines and WHO outbreak detection strategy
A biosimilar application milestone, an AI drug-discovery collaboration and a global surveillance strategy.
Read full update →Pandemic preparedness, RYZ101 radiopharmaceutical trial results and Livmarli rare-disease research
A UN declaration, an investigational cancer therapy update and new evidence in rare cholestatic liver diseases.
Read full update →Kenya Ebola surveillance, remigromig trial results and vamikibart Phase III data
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Laboratory biosafety, biologics manufacturing and early vision-restoration research
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Community mental health care, monthly injectable olanzapine and pritelivir approval
WHO community-care guidance, Teva’s schizophrenia formulation announcement and an FDA infectious-disease approval.
Read full update →Maternal hypertension roadmap, colon cancer treatment approval and Viatris’ proposed Pacira acquisition
WHO maternal-health priorities, an FDA oncology approval and a proposed non-opioid pain portfolio acquisition.
Read full update →Childhood obesity guidance, breast cancer maintenance treatment and AI-ready biology
WHO guidance, an FDA oncology approval and investment in AI biology research.
Read full update →Indian pharma rebranding, rare-disease treatment and infusion care
Novartis India becomes Evonile Pharma; infigratinib receives Priority Review; Option Care acquisition announced.
Read full update →Lymphoma research, measles response and medical-product manufacturing
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →Ibogaine research, radiopharma investment and multi-cancer detection
A source-linked daily briefing on healthcare and pharmaceutical developments.
Read full update →